- Home
- MLTX
as 07-01-2025 1:39pm EST
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
| Founded: | 2021 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 2.8B | IPO Year: | N/A |
| Target Price: | $77.71 | AVG Volume (30 days): | 752.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.42 - $58.26 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 103.42% | Revenue Growth (next year): | N/A |
Latest MoonLake Immunotherapeutics News
MLTX Breaking Stock News: Dive into MLTX Ticker-Specific Updates for Smart Investing
Zacks
a month ago
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
MT Newswires
a month ago
Update: Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise
Yahoo Finance Video
a month ago
Constellation and Meta, Merck, Snowflake: Trending Tickers
Investor's Business Daily
a month ago
MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid
MT Newswires
a month ago
Market Chatter: Merck Held Talks to Buy MoonLake for Over $3 Billion; MoonLake Shares Rise Pre-Bell
Benzinga
a month ago
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Reuters
a month ago
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Newsfile
a month ago
Sienna Resources Inc. Announces Private Placement
Compare MLTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MLTX MoonLake Immunotherapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.